ELYXYB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ELYXYB (ELYXYB).
Topical analgesic; inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in peripheral tissues.
| Metabolism | Hepatic via glucuronidation and oxidation; primarily by UGT2B7 and CYP2C9, with minor contributions from CYP3A4 and CYP2C8. |
| Excretion | Primarily renal excretion of metabolites; 70-80% of dose recovered in urine as glucuronide conjugates, with <1% as unchanged drug. Biliary/fecal excretion accounts for approximately 10-20%. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours in healthy adults. No clinically relevant accumulation with repeated dosing at recommended intervals. |
| Protein binding | Approximately 99% bound, primarily to serum albumin. |
| Volume of Distribution | Following topical administration, systemic absorption is minimal; apparent volume of distribution is not clinically meaningful. After intravenous administration in animal studies, Vd is approximately 0.2 L/kg, consistent with distribution into extracellular fluid. |
| Bioavailability | Topical: Absolute bioavailability is less than 1% due to low systemic absorption following application to the skin or scalp. |
| Onset of Action | Topical: Onset of headache relief within 1 hour post-application, as evidenced by pain freedom at 2 hours in clinical trials. |
| Duration of Action | Duration of effect supports single-dose as-needed use for acute migraine; pain relief sustained for up to 24 hours in some patients, but repeat dosing after 2 hours is recommended if needed. |
Topical application of 5.6 g (one unit dose tube) to the target area of the forehead and temple using the hand-held applicator, applied only once per migraine attack. Maximum dose: 5.6 g per day.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use with caution. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); contraindicated. |
| Pediatric use | Safety and efficacy in pediatric patients (<18 years) have not been established; no recommended dosage. |
| Geriatric use | No dose adjustment required for elderly patients (≥65 years) based on limited data. Use with caution due to potential for increased sensitivity and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ELYXYB (ELYXYB).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Caution advised; consider developmental and health benefits of breastfeeding alongside maternal need for ELYXYB. |
| Teratogenic Risk | No human data; animal studies insufficient to assess risk. Risk cannot be excluded; use only if benefit outweighs potential fetal risk across all trimesters. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to celecoxib or any component of the formulation","History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs","Coronary artery bypass graft surgery","Advanced renal disease","Pregnancy, especially during third trimester"]
| Precautions | ["Risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal; increased risk with longer use or pre-existing cardiovascular disease","Risk of gastrointestinal adverse events including bleeding, ulceration, and perforation","Avoid in setting of coronary artery bypass graft surgery","May cause hypertension, fluid retention, and exacerbation of renal impairment","Anaphylactic reactions may occur","Use with caution in patients with asthma or history of aspirin-sensitive asthma"] |
Loading safety data…
| No specific monitoring required beyond standard obstetric care. Monitor for maternal adverse effects; fetal monitoring not specifically indicated. |
| Fertility Effects | No human data on fertility effects. Animal studies have not been conducted to evaluate impact on fertility. |